Compare Cytokinetics Inc (CYTK) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Dominion Energy Inc — how do they compare? Cytokinetics Inc trades at $81.72 (market cap $11.12B), while Dominion Energy Inc trades at $71.2 (market cap $62.71B). The key difference: Dominion Energy Inc is far larger — about 5.6× Cytokinetics Inc's market cap, and Dominion Energy Inc pays a 3.74% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | D | |
|---|---|---|
Market Cap | $11.12B | $62.71B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $71.32 |
52-Week Low | $33.23 | $56.55 |
Enterprise Value | $11.59B | $115.11B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.
The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
